Habash, S., Abdalla, M., Eskandar, F., Hassan, N. (2019). Circulating sTWEAK Levels and Diabetic Nephropathy in Type 2 Diabetic Patients. Suez Canal University Medical Journal, 22(2), 146-156. doi: 10.21608/scumj.2019.97996
Sara A Habash; Mohamed O Abdalla; Fekry G Eskandar; Nashwa R Hassan. "Circulating sTWEAK Levels and Diabetic Nephropathy in Type 2 Diabetic Patients". Suez Canal University Medical Journal, 22, 2, 2019, 146-156. doi: 10.21608/scumj.2019.97996
Habash, S., Abdalla, M., Eskandar, F., Hassan, N. (2019). 'Circulating sTWEAK Levels and Diabetic Nephropathy in Type 2 Diabetic Patients', Suez Canal University Medical Journal, 22(2), pp. 146-156. doi: 10.21608/scumj.2019.97996
Habash, S., Abdalla, M., Eskandar, F., Hassan, N. Circulating sTWEAK Levels and Diabetic Nephropathy in Type 2 Diabetic Patients. Suez Canal University Medical Journal, 2019; 22(2): 146-156. doi: 10.21608/scumj.2019.97996
Circulating sTWEAK Levels and Diabetic Nephropathy in Type 2 Diabetic Patients
Department of Clinical Pathology, Faculty of Medicine, Suez Canal University, Egypt
Abstract
Background: Diabetic nephropathy (DN) is one of the major complications of diabetes mellitus (DM) that leads to end stage renal disease (ESRD). There is a need for novel biomarkers for early detection and follow up of patients with DN. TNF-like weak inducer of apoptosis (TWEAK) is thought to be involved in the progression of DN through the fibroblast growth factor inducible-14 (Fn14) pathway. Accordingly, blood soluble form of TWEAK (sTWEAK) could be a marker for the progression of and degree of DN. Aim: To assess the relationship between circulating sTWEAK levels and DN in type 2 diabetic patients as it could be a good potential biomarker for detection and follow up of DN patients. Patients and Methods:Sixty type 2 DM patients were selected to be 30 with DN and 30 without DN. DN patients were further divided into 20 microalbuminuric and 10 macro-albuminuric patients. Twenty normal subjects served as a control group. Patients were tested for serum creatinine, lipid prolife, glycated hemoglobin, urinary albumin creatinine ratio (ACR), estimated glomerular filtration rate (eGFR) and serum sTWEAK. Results: Serum sTWEAK was found to change significantly with the level of albuminuria with its lowest level in the macro-albuminuric group (P <0.0001). There was a significant positive correlation between serum sTWEAK and eGFR (r =0.315, p- value =0.014). Furthermore, sTWEAK showed good diagnostic value for detection of macro-albuminuria, with 90% sensitivity and 70% Specificity. Conclusion: Serum sTWEAK could be a good biomarker for detection and follow up of DN.
View on SCiNiTO
Top